ExploreWatchlistsPricing
  1. JP-listed companies
  2. Oncolys BioPharma Inc.
  3. Financials
  4. Total non-current liabilities

Oncolys BioPharma Inc. (4588)

Market cap
¥73.3B
P/E ratio
Develops viral therapies for cancer treatment and severe infections, with lead candidate OBP-301 targeting solid tumors like esophageal cancer.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndTotal non-current liabilities (Million JPY)YoY (%)
Dec 31, 202585-56.15%
Dec 31, 2024194+3.35%
Dec 31, 2023188+10.54%
Dec 31, 2022170-36.47%
Dec 31, 2021268-29.16%
Dec 31, 2020378-6.06%
Dec 31, 2019402+27.03%
Dec 31, 2018317-10.88%
Dec 31, 2017355+11.70%
Dec 31, 2016318-2.88%
Dec 31, 2015328-12.52%
Dec 31, 2014374

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat